Pfizer's Mylotarg Finally Gets CHMP Nod But No New Indication For Sutent

The EMA is finally set to approve Pfizer's targeted anticancer Mylotarg for use in acute myeloid leukemia. The company also received opinions for Bosulif and Sutent.